AR and metastatic prostate carcinoma: The study also found that SLFN11 expression levels were positively correlated with the efficacy of the antibody-drug conjugate B7H3-PBD-ADC in a metastatic prostate cancer model; in particular, high SLFN11 expression was identified as a key factor in sensitivity to the drug in RB1 wild-type (WT) androgen receptor-positive (AR+) patients (13).